Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents

GH Therapy in Partial GHD Adolescents : Evaluation of Efficacy Based on Body Composition and Comparison of 2 Different Doses of Genotonorm®. Open-Label, Randomised, Comparative, Controlled, Parallel-Group, Multi-Center Phase IIIB Clinical Trial.

To evaluate in boys and girls the improvement in body composition under GH treatment in adolescents with CO-GHD who remain partially GHD after GH discontinuation.

Inclusion Criteria:

• Males or females : Chronological age > or = 15 years and < or = 20 years for females
• Chronological age > or = 17 years and < or = 20 years for males
• GHD of childhood onset treated for at least 2 years
• Last GH injection at least 12 months before baseline visit

Exclusion Criteria:

• Turner's syndrome
• Chronic hepatic impairment as shown by GGT and / or ASAT and / or ALAT > 2 X ULN